Clinical Pathology of Lung Cancer
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Pathophysiology".
Deadline for manuscript submissions: 15 April 2025 | Viewed by 43
Special Issue Editor
Interests: lung; kidney; gastrointestinal cancer
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Lung cancer is one of the most common causes of cancer deaths in men and women. Tobacco is the principal cause of lung cancer, but other causes include environmental exposure, asbestos, radon, exposure to ionizing radiation and polycyclic aromatic hydrocarbons. Radiotherapy has also been proposed as a possible contributory cause in patients treated for breast cancer and Hodgkin lymphoma.
On suspicion of lung cancer, CT imaging is necessary to guide diagnosis. Tissue biopsy is mandatory to determine the histological type of tumor and will guide both the molecular investigations and the biomarkers performed. Once the diagnosis has been made, it is desirable to perform a PET scan to understand the extent of the disease, and brain magnetic resonance imaging (MRI) to assess if there are brain metastases and complete the disease staging.
Early diagnosis and the therapeutic innovations which have appeared in recent years (targeted therapies or different modalities of immunotherapy) have changed the therapeutic approach and also the course of the disease. At the same time, current therapies have highlighted new toxicities and resistances that increasingly lead to re-biopsy and liquid biopsy for the evaluation of minimal residual disease too.
For all these reasons, we believe that this Special Issue will be of interest to all medical specialties that contribute to the diagnosis and treatment of lung cancer.
Dr. Letizia Gnetti
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- lung cancer
- pathology
- diagnosis
- treatment
- targeted therapies
- immunotherapy
